Stock Worth Mentioning Today: Is Buying Alnylam Pharmaceuticals, Inc. Here a Winning Strategy?

Stock Worth Mentioning Today: Is Buying Alnylam Pharmaceuticals, Inc. Here a Winning Strategy?

The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a huge mover today! About 1.24M shares traded hands. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 53.49% since April 4, 2016 and is downtrending. It has underperformed by 54.58% the S&P500.
The move comes after 8 months positive chart setup for the $2.78 billion company. It was reported on Nov, 4 by We have $40.00 PT which if reached, will make NASDAQ:ALNY worth $556.00M more.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 earnings per share, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage

Out of 14 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 8 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 57% are positive. Alnylam Pharmaceuticals has been the topic of 29 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Janney Capital on Thursday, September 29 with “Neutral”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Friday, August 5 by Jefferies. The rating was maintained by JMP Securities with “Outperform” on Friday, August 28. The stock has “Buy” rating given by Jefferies on Friday, October 23. Barclays Capital downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Barclays Capital has “Equal-Weight” rating and $50 price target. Chardan Capital Markets maintained the shares of ALNY in a report on Thursday, October 6 with “Buy” rating. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Buy” rating by Jefferies on Thursday, October 6. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Mkt Perform” rating by Leerink Swann on Thursday, October 6. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Overweight” rating by JP Morgan on Friday, August 5.

According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”

Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio dived, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
Raymond James & Assocs has 0% invested in the company for 4,008 shares. Gsa Cap Prns Limited Liability Partnership has invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The Maryland-based Profund Ltd Liability has invested 0.11% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The California-based Franklin Resources has invested 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blue Ridge Capital Lc last reported 1.32M shares in the company. Moreover, Wfg Advisors L P has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 750 shares. Dodge And Cox last reported 2.52M shares in the company. Macquarie Gp Limited has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Employees Retirement Association Of Colorado accumulated 0.01% or 17,829 shares. State Street Corp owns 2.20 million shares or 0.01% of their US portfolio. Jennison Assoc Ltd Liability holds 975,425 shares or 0.06% of its portfolio. Wellington Grp Llp holds 0.17% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 11.97M shares. Credit Agricole S A holds 0% or 12,824 shares in its portfolio. Mycio Wealth Prtnrs Limited holds 0.01% or 1,500 shares in its portfolio. Ls Advsrs Limited Liability Com accumulated 1,548 shares or 0.01% of the stock.

Insider Transactions: Since July 19, 2016, the stock had 1 insider buy, and 1 insider sale for $918,262 net activity. 30,151 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares with value of $1.95M were sold by MARAGANORE JOHN. On Thursday, October 13 PYOTT DAVID E I bought $1.03 million worth of the stock or 27,900 shares.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: which released: “Alnylam Pharmaceuticals Slid 12.6% Today After Earnings” on November 03, 2016, also with their article: “What’s Next for Alnylam Pharmaceuticals, Inc. After Its Phase 3 Failure?” published on October 07, 2016, published: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: and their article: “Lifshitz & Miller Law Firm Announces Investigation of Alnylam Pharmaceuticals …” published on October 28, 2016 as well as‘s news article titled: “Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt” with publication date: October 10, 2016.

ALNY Company Profile

Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment